Q-omics provides the consensus-scored COL25A1-DT profile across patient tissues and cancer cell-line models. COL25A1-DT expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, COL25A1-DT is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, COL25A1-DT RNA expression shows 12,558 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCS, THCA, and UVM as cancer lineages where COL25A1-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COL25A1-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COL25A1-DT survival associations across molecular data types. COL25A1-DT RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COL25A1-DT RNA expression–survival associations across cancer types. High COL25A1-DT expression shows unfavorable associations in ESCA, UCEC and UVM, but favorable associations in UCS, MESO and BLCA. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for COL25A1-DT RNA expression.
This table summarizes COL25A1-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for COL25A1-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COL25A1-DT shows lower tumor expression in THCA, BRCA, COAD, READ and LUSC and higher tumor expression in LUAD. The THCA box plot shows higher COL25A1-DT RNA expression in normal versus tumor tissue (log2 FC = −0.115, t-test p < 0.001).
This table shows molecular features associated with COL25A1-DT in patient tissues and cancer cell lines. In patient samples, COL25A1-DT shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
